Therapeutics: New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty

BMJ

Volumn 342, Issue 7790, 2011, Pages 224-227

  Eikelboom, John W ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APIXABAN; DABIGATRAN ETEXILATE; FONDAPARINUX; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CASE REPORT; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; DRUG INTERACTION; KIDNEY DISEASE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; KIDNEY DISEASES; MORPHOLINES; PYRIDINES; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 78751681306     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c7270     Document Type: Article

References (20)

1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32.
2. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. (Clinical guidance 92.) 2010. http://guidance.nice.org.uk/CG92.
3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(suppl 6):381-453S. (Pubitemid 351894916)
4. FDA approves Pradaxa [dabigatran etexilate] to prevent stroke in people with atrial fibrillation. FDA news release. October 2010. www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm
5. PRADAX (dabigatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation. www.boehringer-ingelheim.com/news/news- releases/press-releases/2010/27-october-2010-dabigatran.html
6. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
7. New medicine to reduce thrombosis (blood clotting) after hip replacement surgery. www.ehaweb.org/news/Press-Releases-15th-Congress-of-the-EHA/New- medicine-to-reduce-thrombosis. 2010
8. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
9. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1-9.
10. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
11. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
12. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
13. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80.
14. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010;51:113-23.
15. Van RJ, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
16. Product Monograph. Pradax. Boehringer Ingelheim. 2010. www.boehringer-ingelheim.ca/en/Home/Human-Health/Our-Products/ Product-Monographs/Pradaxpm.pdf
17. Product Monograph. Xarelto. Bayer. 2008. www.bayer.ca/files/XARELTO-PM- ENG-10SEP2008-119111.pdf.
18. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22.
19. Apostolakis S, Shantsila E, Lip GY. New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness? Pharmacoeconomics 2009;27:793-95.
20. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829-46.